Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Sold by Citigroup Inc.

Citigroup Inc. cut its holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 20.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,025,418 shares of the biotechnology company’s stock after selling 264,213 shares during the period. Citigroup Inc. owned 1.08% of Atara Biotherapeutics worth $3,363,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ATRA. State Street Corp lifted its holdings in Atara Biotherapeutics by 45.1% in the first quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock valued at $58,282,000 after acquiring an additional 1,949,418 shares during the last quarter. Wasatch Advisors Inc. raised its position in Atara Biotherapeutics by 88.8% in the first quarter. Wasatch Advisors Inc. now owns 3,823,588 shares of the biotechnology company’s stock valued at $35,521,000 after purchasing an additional 1,798,072 shares during the period. Goldman Sachs Group Inc. raised its position in Atara Biotherapeutics by 41.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,638,106 shares of the biotechnology company’s stock valued at $33,798,000 after purchasing an additional 1,073,579 shares during the period. Renaissance Technologies LLC purchased a new stake in Atara Biotherapeutics in the first quarter valued at approximately $5,293,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Atara Biotherapeutics in the third quarter valued at approximately $1,343,000.

Insider Buying and Selling at Atara Biotherapeutics

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 29,766 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $2.04, for a total value of $60,722.64. Following the sale, the chief executive officer now directly owns 720,962 shares in the company, valued at $1,470,762.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 77,918 shares of company stock worth $209,586 over the last ninety days. Corporate insiders own 4.50% of the company’s stock.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock opened at $2.10 on Tuesday. Atara Biotherapeutics, Inc. has a 1-year low of $1.94 and a 1-year high of $9.34. The stock has a market cap of $205.74 million, a PE ratio of -1.01 and a beta of 0.96. The stock’s fifty day moving average is $2.72 and its two-hundred day moving average is $3.63.

Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.32). Atara Biotherapeutics had a negative net margin of 373.95% and a negative return on equity of 166.74%. The business had revenue of $1.23 million during the quarter, compared to analyst estimates of $37.67 million. On average, research analysts expect that Atara Biotherapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ATRA shares. StockNews.com lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. HC Wainwright cut their price objective on Atara Biotherapeutics from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, February 9th. Mizuho reaffirmed a “buy” rating and set a $31.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, February 7th. Finally, EF Hutton Acquisition Co. I reaffirmed a “buy” rating and set a $25.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, February 9th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Hold” and an average price target of $19.25.

Atara Biotherapeutics Profile

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need.